Home
/
Taysha Gene Therapies, Inc.
/
Financials
/
Quarterly
Taysha Gene Therapies, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Taysha Gene Therapies, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 4, 2025
Q2
2025
Jun 30, 2025
$1.99M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$2.30M
May 15, 2025
Q3
2025
Sep 30, 2024
$1.79M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$1.11M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$3.41M
May 15, 2025
Q3
2024
Sep 30, 2023
$4.75M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$2.40M
Aug 12, 2024
Q1
2024
Mar 31, 2023
$4.71M
May 14, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($32.73M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($26.88M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($21.53M)
May 15, 2025
Q3
2025
Sep 30, 2024
($25.52M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($20.93M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($24.06M)
May 15, 2025
Q3
2024
Sep 30, 2023
($117.09M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($24.60M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($17.62M)
May 14, 2024
Q3
2023
Sep 30, 2022
($26.53M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($34.09M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($50.32M)
May 11, 2023
Q3
2022
Sep 30, 2021
($51.19M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($40.93M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($32.02M)
May 16, 2022
Q3
2021
Sep 30, 2020
($15.04M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($21.22M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($5.43M)
May 11, 2021
Q3
2020
Sep 30, 2019
($31.0K)
Nov 12, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($34.02M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($26.75M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($21.42M)
May 15, 2025
Q3
2025
Sep 30, 2024
($25.90M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($21.30M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($24.33M)
May 15, 2025
Q3
2024
Sep 30, 2023
($16.25M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($23.38M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($16.56M)
May 14, 2024
Q3
2023
Sep 30, 2022
($25.46M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($33.37M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($49.65M)
May 11, 2023
Q3
2022
Sep 30, 2021
($50.68M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($40.77M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($32.09M)
May 16, 2022
Q3
2021
Sep 30, 2020
($15.04M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($4.01M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($5.58M)
May 11, 2021
Q3
2020
Sep 30, 2019
($31.0K)
Nov 12, 2020